Why the study?
Data on early and late outcomes following TAVI and SAVR in obese patients were limited, raising the question of whether TAVI is superior to SAVR in this population.
Does TAVI improve long-term survival compared to SAVR in obese patients?
Observational
Yes
Does TAVI improve long-term survival compared to SAVR in obese patients?
In obese patients requiring aortic valve replacement, SAVR is associated with significantly higher long-term survival rates up to 5 years compared to TAVI.
Answers are grounded in this paper and cite their sources.
SAVR was associated with higher survival than TAVI in obese patients; leaves open whether RCTs will confirm this before practice change.
INTRODUCTION: Data on the early and late outcome following transcatheter aortic valve implantation (TAVI) and surgical aortic valve replacement (SAVR) in obese patients are limited. We investigated whether TAVI may be superior to SAVR in obese patients. MATERIAL AND METHODS: ) who underwent either SAVR or TAVI were identified from the nationwide OBSERVANT registry, and their in-hospital and long-term outcomes were analysed. Propensity score matching was employed to identify two cohorts with similar baseline characteristics. CONCLUSIONS: In obese patients, both SAVR and TAVI are valid treatment options, although in the long term SAVR exhibited higher survival rates.
No takes yet. Share an insight, caveat, or question.
Mariscalco et al. (2019) conducted an observational in Aortic valve replacement in obese patients. Transcatheter aortic valve replacement vs. Surgical aortic valve replacement was evaluated.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: